oalib
Search Results: 1 - 10 of 100 matches for " "
All listed articles are free for downloading (OA Articles)
Page 1 /100
Display every page Item
Cancer Intralesion Chemotherapy with Solasodine Rhamnosyl Glycosides
Bill E. Cham
Research Journal of Biological Sciences , 2012,
Abstract: Solasodine rhamnosyl glycosides (SRGs) are a new class of chemotherapeutic agents for the treatment of cancer. SRGs in a cream formulation CuradermBEC5 is now available for the treatment of skin cancers. Phase 2 clinical trials with intravenous (i.v.) administration of SRGs on patients with internal cancers are currently being done. The specificity and mode of action of SRGs are vastly different than those of other traditional anti-mitotic anticancer drugs. These differences have now led to SRGs intralesion chemotherapy, a very effective, new safer, anticancer modality, resulting in rapid regression of solid tumours using 1% of the dose that is required when compared with SRGs i.v. administration. In this feasibility pilot study large external tumours of animals and man were injected intralesionally with SRGs. Results demonstrate that SRGs when injected intralesionally successfully dispose of large tumours without any clinical adverse effects and that apoptosis is the cause of cancer cell death.
Cancer Intralesion Chemotherapy with Solasodine Rhamnosyl Glycosides
Bill E. Cham
Research Journal of Biological Sciences , 2008,
Abstract: Solasodine rhamnosyl glycosides (SRGs) are a new class of chemotherapeutic agents for the treatment of cancer. SRGs in a cream formulation CuradermBEC5 is now available for the treatment of skin cancers. Phase 2 clinical trials with intravenous (i.v.) administration of SRGs on patients with internal cancers are currently being done. The specificity and mode of action of SRGs are vastly different than those of other traditional anti-mitotic anticancer drugs. These differences have now led to SRGs intralesion chemotherapy, a very effective, new safer, anticancer modality, resulting in rapid regression of solid tumours using 1% of the dose that is required when compared with SRGs i.v. administration. In this feasibility pilot study large external tumours of animals and man were injected intralesionally with SRGs. Results demonstrate that SRGs when injected intralesionally successfully dispose of large tumours without any clinical adverse effects and that apoptosis is the cause of cancer cell death.
Topical Solasodine Rhamnosyl Glycosides Derived From the Eggplant Treats Large Skin Cancers: Two Case Reports  [PDF]
Bill E. Cham
International Journal of Clinical Medicine (IJCM) , 2011, DOI: 10.4236/ijcm.2011.24080
Abstract: Solasodine rhamnosyl glycosides (BEC) are a new class of antineoplastics that show superior efficacy than many established anticancer drugs as shown by intravenous, intraperitoneal and intralesion administrations. Previous studies have described the efficacy of BEC on nonmelanoma skin cancers by topical application. Two cases are now reported which show that BEC in a cream formulation Curaderm is very effective for the treatment of large nonmelanoma skin cancers that are considered difficult to treat by existing modalities. Moreover, the cosmetic outcomes are very impressive.
Solasodine, Solamargine and Mixtures of Solasodine Rhamnosides: Pathway to Expansive Clinical Anticancer Therapies  [PDF]
Bill E. Cham
International Journal of Clinical Medicine (IJCM) , 2017, DOI: 10.4236/ijcm.2017.812064
Abstract: Cancer remains a major cause of mortality worldwide. Progresses have been made in the understanding of the molecular basis of cancer, cancer detection, and cancer treatment. Important strides by treating early-stage cancers have resulted in improved outcomes. Despite these achievements, mortality of cancer patients is high and still there is no cure. Some oncologists remain optimistic that cytotoxic chemotherapy will significantly improve cancer survival. However, notwithstanding the use of new and expensive single and more recently, combination drugs, the improvement of the response rates remains very low. In the United States, cancer death rates decreased by a mere 1.4% to 1.8% from 2004 to 2013. Compared to other serious diseases, the improvement of the cancer patient has been disappointingly lagging, and by far, most patients with advanced cancer eventually die of their disease. The need for improved cancer therapies is self-evident. This communication gives an overview of the overwhelming resurgence of solasodine and its glycosides in cancer therapy.
Solasodine Rhamnosyl Glycosides in a Cream Formulation is Effective for Treating Large and Troublesome Skin Cancers
Bill E. Cham
Research Journal of Biological Sciences , 2012,
Abstract: It is now established that solasodine rhamnosyl glycosides (BEC) are antineoplastics. Specificity of BEC to interact with particular receptors on tumour cells relative to normal cells and the involvement of the sugar rhamnose, conjugated to the glycoalkaloids BEC, as a key molecule to gain entry into cancer cells but not normal cells has been established. Once the BEC-receptor is inside the cell by the receptor-mediated endocytosis process, the complex is eventually taken up by the lysosomes. BEC then induces the lysosome to rupture causing immediate cancer cell death by apoptosis. It is now accepted that BEC formulated in a topical cream is effective for treating non-melanoma skin cancers Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC). Previous studies have described the efficacy of BEC on non-melanoma skin cancers that approximate lesion sizes of the general population. In this study, large non-melanoma skin cancers were treated with BEC as well as non-melanoma skin cancers located in areas of the body that are considered difficult to treat by any existing modality. Eight patients with BCCs and 11 patients with SCCs were treated and after treatment, were followed-up for at least 5 years. The results indicate that BEC can successfully dispose of large and difficult to treat BCCs and SCCs. Furthermore, the results demonstrate that the cosmetic effect after BEC therapy is superior to other treatment methods.
Solasodine Rhamnosyl Glycosides in a Cream Formulation is Effective for Treating Large and Troublesome Skin Cancers
Bill E. Cham
Research Journal of Biological Sciences , 2007,
Abstract: It is now established that solasodine rhamnosyl glycosides (BEC) are antineoplastics. Specificity of BEC to interact with particular receptors on tumour cells relative to normal cells and the involvement of the sugar rhamnose, conjugated to the glycoalkaloids BEC, as a key molecule to gain entry into cancer cells but not normal cells has been established. Once the BEC-receptor is inside the cell by the receptor-mediated endocytosis process, the complex is eventually taken up by the lysosomes. BEC then induces the lysosome to rupture causing immediate cancer cell death by apoptosis. It is now accepted that BEC formulated in a topical cream is effective for treating non-melanoma skin cancers Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC). Previous studies have described the efficacy of BEC on non-melanoma skin cancers that approximate lesion sizes of the general population. In this study, large non-melanoma skin cancers were treated with BEC as well as non-melanoma skin cancers located in areas of the body that are considered difficult to treat by any existing modality. Eight patients with BCCs and 11 patients with SCCs were treated and after treatment, were followed-up for at least 5 years. The results indicate that BEC can successfully dispose of large and difficult to treat BCCs and SCCs. Furthermore, the results demonstrate that the cosmetic effect after BEC therapy is superior to other treatment methods.
Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers
Bill E. Cham
Research Journal of Biological Sciences , 2012,
Abstract: Cattle farmers in Australia have proclaimed that crushing and application of the fruit of a weed known as Devil s Apple retarded the progress of ocular squamous cell carcinoma in Hereford cattle. The Devil s Apple plant, Solanum linnaeanum (also known as Solanum sodomaeum and Solanum hermannii), is a member of the same family as eggplant, potatoes and tomatoes. In 1987 it was reported that the fruit of the Devil s Apple plant contained a mixture of solasodine glycosides. The mixture of solasodine glycosides was constant when extracted from the fruits of the Devil s Apple plant and was given the name BEC which consisted of the triglycosides solasonine, solamargine and di-and monoglycosides. All the glycosides contained the same aglycone an alkaloid solasodine and the sugar moiety consisted of rhamnose, glucose and galactose. BEC has antineoplastic properties against a wide variety of human cancers in cell culture, tissue culture and is very effective against terminal tumours in animals. BEC not only prolonged the life of animals with terminal cancers, but the cancers were completely eliminated rendering the animals cancer free for the remainder of their normal life span. BEC in a topical cream formulation is now available clinically for the treatment of non malignant and malignant human skin cancers. BEC is very selective in killing cancer cells without harming normal cells due to a unique mode of action. In addition BEC exerts its antineoplastic activity on cancer cells at proliferative as well as "resting" (nonproliferative) stages of their life cycles. BEC, due to its selectivity and efficacy is superior to other well established antineoplastics. The observations that BEC has good antineoplastic activities, together with a very high safety profile, have paved the way for much work currently being undertaken to establish the potential of BEC as a new antineoplastic agent for internal cancers.
Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers
Bill E. Cham
Research Journal of Biological Sciences , 2007,
Abstract: Cattle farmers in Australia have proclaimed that crushing and application of the fruit of a weed known as Devil`s Apple retarded the progress of ocular squamous cell carcinoma in Hereford cattle. The Devil`s Apple plant, Solanum linnaeanum (also known as Solanum sodomaeum and Solanum hermannii), is a member of the same family as eggplant, potatoes and tomatoes. In 1987 it was reported that the fruit of the Devil`s Apple plant contained a mixture of solasodine glycosides. The mixture of solasodine glycosides was constant when extracted from the fruits of the Devil`s Apple plant and was given the name BEC which consisted of the triglycosides solasonine, solamargine and di-and monoglycosides. All the glycosides contained the same aglycone an alkaloid solasodine and the sugar moiety consisted of rhamnose, glucose and galactose. BEC has antineoplastic properties against a wide variety of human cancers in cell culture, tissue culture and is very effective against terminal tumours in animals. BEC not only prolonged the life of animals with terminal cancers, but the cancers were completely eliminated rendering the animals cancer free for the remainder of their normal life span. BEC in a topical cream formulation is now available clinically for the treatment of non malignant and malignant human skin cancers. BEC is very selective in killing cancer cells without harming normal cells due to a unique mode of action. In addition BEC exerts its antineoplastic activity on cancer cells at proliferative as well as "resting" (nonproliferative) stages of their life cycles. BEC, due to its selectivity and efficacy is superior to other well established antineoplastics. The observations that BEC has good antineoplastic activities, together with a very high safety profile, have paved the way for much work currently being undertaken to establish the potential of BEC as a new antineoplastic agent for internal cancers.
Intralesion and CuradermBEC5 Topical Combination Therapies of Solasodine Rhamnosyl Glycosides Derived from the Eggplant or Devil’s Apple Result in Rapid Removal of Large Skin Cancers. Methods of Treatment Compared  [PDF]
Bill E. Cham
International Journal of Clinical Medicine (IJCM) , 2012, DOI: 10.4236/ijcm.2012.32024
Abstract: Solasodine rhamnosyl glycosides (SRGs) are chemotherapeutic agents for the treatment of cancer. SRGs in a cream formulation, CuradermBEC5, is very effective for the treatment of nonmelanoma skin cancers with excellent cosmetic end results. Intralesion injection of SRGs successfully dispose of very large tumours in animals without any clinical adverse effects. The mode of action of SRGs is by apoptosis. In this study, it is shown that small to large basal cell carcinomas are effectively treated only with topical application of CuradermBEC5. Here it is reported for the first time that combination of intralesion SRG injection and topical application with CuradermBEC5 in humans reduces the treatment time period by more than half when compared with topical application as the sole treatment regime. Two intralesion injections of very low doses of SRGs rapidly and effectively remove a large melanoma on a horse. If rapid removal of large troublesome skin cancers is required then this can be achieved by intralesion and topical treatments. Intralesion or combination therapy with SRGs may have some applications for melanomas in situ such as lentigo maligna.
CuradermBEC5 for Skin Cancers, Is It? An Overview  [PDF]
Tania Robyn Chase
Journal of Cancer Therapy (JCT) , 2011, DOI: 10.4236/jct.2011.25099
Abstract: Skin cancer incidence is increasing at alarming rates and is considered by some as an epidemic. Its incidence is higher than all other cancers combined. The developments of new treatments have not parallelled the increased incidences of this disease. A variety of treatments are available with differing outcomes. More recently a novel topical treatment, consisting of the antineoplastic compounds solasodine rhamnosyl glycosides, solamargine and solasonine, which are derived from plant material, has been described that claims to have many advantages over the currently used skin cancer therapies. This review investigates such claims.
Page 1 /100
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.